Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%82 EV-to-EBIT is 12.45 as of Jul. 22, 2026, which is 74% below its 10-year median of 47.31. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 60.68% on this metric.
The historical rank and industry rank for Surgical Science Sweden AB's EV-to-EBIT or its related term are showing as below:
SUSRF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -340.21 Med: 47.31 Max: 2744.39
Current: 12.93
During the past 11 years, the highest EV-to-EBIT of Surgical Science Sweden AB was 2744.39. The lowest was -340.21. And the median was 47.31.
SUSRF's EV-to-EBIT is ranked better than 60.68% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 15.775
vs SUSRF: 12.93
Surgical Science Sweden AB (OTCPK:SUSRF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Surgical Science Sweden AB's Enterprise Value for the quarter that ended in Mar. 2026 was $73.5 Mil.
Surgical Science Sweden AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB EV-to-EBIT Related Terms
Surgical Science Sweden AB EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Surgical Science Sweden AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's EV-to-EBIT falls into.
Surgical Science Sweden AB's current Enterprise Value is $91.4 Mil.
Surgical Science Sweden AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a EV-to-EBIT of 12.45 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Surgical Science Sweden AB and its competitors. This is 74% below median its historical median of 47.31. According to the industry distribution chart, Surgical Science Sweden AB ranks #184 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 39.3%.
Is Surgical Science Sweden AB's EV-to-EBIT too high?
Surgical Science Sweden AB's current EV-to-EBIT of 12.45 is 74% below median its 10-year median of 47.31. The Healthcare Providers & Services industry median EV-to-EBIT is 15.78. Surgical Science Sweden AB's value of 12.45 is 21.1% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #184 out of 468 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #184 out of 468 companies for EV-to-EBIT. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median EV-to-EBIT is 15.78. Surgical Science Sweden AB's value of 12.45 is 21.1% below this benchmark. While the company's 10-year median is 47.31 vs. the industry median of 15.78, Surgical Science Sweden AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.78, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current EV-to-EBIT of 12.45 is 21.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current EV-to-EBIT is 12.45, which is 74% below median its own 10-year median of 47.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.25, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current EV-to-EBIT is 12.45, which is 74% below median its 10-year median of 47.31 and 21.1% below the Healthcare Providers & Services industry median of 15.78. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current EV-to-EBIT is 12.45 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.25.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
EV-to-EBIT: 12.45 (74% below median its 10-year median of 47.31)
GF Value™: $14.25 vs. price of $4.00 (71.9% below fair value)
Industry Position: 21.1% below the Healthcare Providers & Services median (#184 of 468)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
